Connect
MJA
MJA

Severe symptomatic hypocalcaemia following a single dose of denosumab

Jennifer M McLachlan, Gavin M Marx and Margaret Bridgman
Med J Aust 2013; 199 (4): . || doi: 10.5694/mja13.10038
Published online: 2 September 2013

To the Editor: Denosumab, a receptor activator of nuclear factor κ-B (RANK) ligand inhibitor, is now considered first-line therapy to prevent skeletal-related events in patients with bone metastases secondary to breast cancer and castration-resistant prostate cancer.1,2


  • Sydney Adventist Hospital, Sydney, NSW.


Correspondence: jenny.clare@gmail.com

Acknowledgements: 

We thank the patient for allowing us to report this case.

Competing interests:

No relevant disclosures.

  • 1. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
  • 2. Stopeck AT, Lipton A, Body J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomised, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
  • 3. Autio KA, Farooki A, Glezerman I, et al. Risk assessment for severe hypocalcemia requiring hospitalisation with denosumab [abstract]. J Clin Oncol 2013; 31 Suppl 6: abstr 115.
  • 4. Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471-1479.
  • 5. Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ 2008; 336: 1298.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.